Myosin Inhibitor

ME-3407 (EF-4040) is a H⁺-K⁺-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H⁺-K⁺-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer.

Blebbistatin (Standard) is the analytical standard of Blebbistatin. This product is intended for research and analytical applications. Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration.

ZJS178 is a novel inhibitor of myosin I. ZJS178 is a fungicide that has inhibitory activity against Fusarium graminearum and can reduce DON toxin synthesis. ZJS178 can be used for research on plant diseases such as wheat scab.

ML-7 is a selective and highly specific myosin light chain kinase (MLCK) inhibitor that acts as a trabecular meshwork (TM) relaxant. ML-7 enhances Quinocetone (HY-123581)-induced phosphorylation of ERK, p38 MAPK and JNK, attenuates Akt activation, and promotes apoptosis of hepatocellular carcinoma cells. ML-7 reduces Th2 cytokine secretion by inhibiting MLCK, while alleviating smooth muscle hyperplasia and collagen deposition. As a non-antibiotic adjuvant, ML-7 restores the sensitivity of drug-resistant bacteria to Tigecycline (HY-B0117). ML-7 can be used in research related to glaucoma, hepatocellular carcinoma, asthma, and Klebsiella pneumoniae infection.

Ruberythric acid is a natural product found in madder (Rubia tinctorum). Acid treatment induces hydrolysis of Ruberythric acid, producing pentose-containing sugar residues and alizarin. Ruberythric acid inhibits stimulus-induced phosphorylation of IKK, IκBα and p65 in the NF-κB pathway, regulates tight junction integrity, suppresses stimulus-induced MLCK activation and myosin light chain phosphorylation, reduces tight junction disruption associated with cytoskeletal contraction, alleviates stimulus-induced increase in intestinal permeability, and prevents stimulus-induced redistribution of tight junction proteins. Ruberythric acid forms red salts when dissolved in alkali and can be used as a dye. Ruberythric acid is applicable to research related to inflammatory bowel disease.

W-7 (hydrochloride) (Standard) is the analytical standard of W-7 (hydrochloride) (HY-100912). This product is intended for research and analytical applications. W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias.

(+)-Blebbistatin (Standard) is the analytical standard of (+)-Blebbistatin (HY-107657). This product is intended for research and analytical applications. (+)-Blebbistatin is the inactive enantiomer of (-)-Blebbistatin (HY-13441). (-)-Blebbistatin is a selective inhibitor of non-muscle myosin II ATPase activity.

HA-100 (Standard) is the analytical standard of HA-100 (HY-100984). This product is intended for research and analytical applications. HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor.

(-)-Blebbistatin (Standard) is the analytical standard of (-)-Blebbistatin (HY-13441). This product is intended for research and analytical applications. (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.

ATM-3507 (Standard) is the analytical standard of ATM-3507 (HY-100948). This product is intended for research and analytical applications. ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.

Myosin-5-IN-2 (Compound G19) is a Myosin-5 inhibitor. Myosin-5-IN-2 has an antifungal activity against Fusarium graminearum (Fg), Botrytis cinerea and Rhizoctonia solani with an EC₅₀ s of 0.326 μg/mL for Fg. Myosin-5-IN-2 has effective protective and curative control efficiency for wheat leaves. Myosin-5-IN-2 severely damages the surface integrity of mycelial cells and induces cytoplasmic leakage. Myosin-5-IN-2 can be used for fungal infections like fusarium head blight (FHB) research.

Aficamten-d₃ (CK-274-d₃) is deuterium labeled Aficamten. Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC₅₀ of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).

Troponin I (104-115) is a polypeptide derived from Troponin I. Troponin I is an inhibitor of Acto-S1-TM ATPase, with an IC₅₀ of 2.25 μM against skeletal muscle Acto-S1-TM ATP enzyme. Troponin I is used in research on muscle contraction-relaxation and restrictive cardiomyopathy.

(R)-(+)-Blebbistatin O-Benzoate is a non-muscle myosin II selective inhibitor. (R)-(+)-Blebbistatin O-Benzoate is a derivative of Blebbistatin (HY-13813). (R)-(+)-Blebbistatin O-Benzoate blocks cell membrane bubbling and interferes with directed migration and cytokinesis in vertebrate cells. (R)-(+)-Blebbistatin O-Benzoate inhibits the contraction of mitotic grooves. (R)-(+)-Blebbistatin O-Benzoate can be used as a negative control for (S)-(-)-Blebblastatin.

ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.

Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC₅₀s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch.